In a statement, Johnson & Johnson reiterated that the chances of those who get the vaccine developing Guillain-Barré is very low. and "the safety and well-being of the people who use our products is our number one priority."
Thank you for reading until the last page! We would love to hear your opinions and feedback. Click the thumbs-up below and type in what you want us to know. Alternatively, you could shoot an email to [email protected].
¿Fue útil esta página ¡Danos un pulgar hacia arriba!
+1Útil ( 48 )
Inútil ( 7 )
Entregar
¡Gracias por tus comentarios!
